alexa Metformin is Beneficial in DM2 Patients with Prostate Cancer | Open Access Journals
Journal of Prostate Cancer
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Metformin is Beneficial in DM2 Patients with Prostate Cancer

Chong RW1, Vasudevan V2, Zuber3 and Solomon SS4*

1M-3 UTHSC Memphis, USA

2Department of Endocrinology, UTHSC, Memphis, USA

3Department of Preventive Medicine, UTHSC, USA

4Department of Endocrinology and Metabolism, Medical and Research Services, VAMC Professor of Medicine (Endocrinology) and Pharmacology, COM UTHSC, Memphis, USA

*Corresponding Author:
Solomon SS
M.D. Chief Endocrinology and Metabolism Medical and Research Services
VAMC Professor of Medicine (Endocrinology) and Pharmacology
COM UTHSC, Memphis, USA
Tel:+901-523-8990
E-mail: [email protected]

Received Date: February 15, 2016; Accepted Date: February 17, 2016; Published Date: February 24, 2016

Citation: Chong RW, Vasudevan V, Zuber, Solomon SS (2016) Metformin is Beneficial in DM2 Patients with Prostate Cancer. JPS Open Access 1:101.

Copyright: © 2016 Chong RW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Prostate Cancer

Opinion

Two years ago we became aware of the use of metformin as adjuvant therapy in breast cancer. We were curious to see if the metformin was effective in male prostate cancer, in some sense an endocrinologic equivalent of breast cancer in men. In a retrospective chart review, Prostate cancer patients with DM 2 were identified in the electronic record system of the VA (CPRS). One group had control of their Diabetes with standard therapy and no metformin and a matched group had control of their Diabetes with standard therapy plus metformin. We examined the final PSA values, number of recurrences, metastases and number living for each group. There were significantly fewer deaths (-13%), recurrences (-7%), metastases (5% for control, 0% for metformin) and fewer secondary cancers (-11%), with a p<0.004 cumulative value for all cancer related issues. PSA was lower in the metformin group, with a p value approaching significance. We believe these significant effects involve metformin’s ability to activate AMPK, a kinase, which inhibits mTOR. AMPK is an energy signaling molecule and it and mTOR, regulating cell growth are found in many cancers including prostate. In addition, metformin activates several tumor suppressor genes including the well-known p53 gene. Many of the signaling pathways that make metformin very useful in DM 2 appear also to be involved in cancer “signaling”. We believe metformin works to enhance cytotoxic effects of other traditional chemotherapy. Because this is a retrospective study, we believe a prospective double blind clinical trial will be needed to confirm our preliminary findings [1,2].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 8006
  • [From(publication date):
    April-2016 - Nov 18, 2017]
  • Breakdown by view type
  • HTML page views : 7927
  • PDF downloads : 79

Review summary

  1. Lily Jackson
    Posted on Oct 20 2016 at 3:18 pm
    The article discussed the therapeutic role of Metformin in the treatment of breast cancer. The article also highlighted the possible application of metformin in the treatment of prostate cancer. The idea is intriguing and supported by some clinical studies, but the wide spread application of metformin for prostate cancer patients should be based on concrete molecular and clinical evidences.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords